Wednesday, January 27, 2021

Curis, Inc. (CRIS) Skyrocketed up to 450% on Tuesday After Positive Phase 1 Results of leukemia Study

Must read

8×8 Inc (EGHT) Joins hand with Verint Systems Inc. (VRNT)

8x8, Inc.(EGHT), a provider of communication solutions for the enterprise, and Verint Systems Inc. (NASDAQ: VRNT), a provider of security and optimization solutions for...

PACCAR Inc (PCAR) Deal allows Aurora Autonomous Truck Validation

Aurora, a Silicon Valley-based autonomous driving startup with a $10 billion evaluation has entered a partnership with PACCAR Inc (PCAR),  to make light, medium...

COVAX to receive up to 40 million doses of COVID-19 vaccine from Pfizer and BioNTech

The Coronavirus vaccine developed by Pfizer Inc. and BioNTech SE will provide 40 million doses to the COVAX vaccine distribution program, aiming to take...

Don’t Ignore This Blaring Warning Signal from iRobot Corp (IRBT)

iRobot Corp. (NASDAQ: IRBT), a cleaning equipment manufacturer, experienced more than a 110% rise in its shares during the past 12 months. As a...

The small-cap biotech has reported positive data from phase 1 trials of CA-4948. Curis has also announced its public offering for the common stock.

Curis, Inc. (CRIS) is all bullish following the release of positive preliminary data of its Phase 1 trials of CA-4948. The company is working on its ongoing open-label and single arm dose escalation study to evaluate the efficacy and tolerance of CA-4948 in leukemia patients.


5 Stocks to make up the PERFECT 2021 gold portfolio

Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.

Click here to download your free report right away

Sponsored


Curis was a titan in the market on Dec. 8 as the stock rallied up to 450% trading at a 52-week high of $7.90. CRIS shares kicked off at $5.47 from the prior close of $1.44. The positive data from small molecule IRAK4 kinase inhibitor for leukemia patients had the stock soared with high volume.

CRIS was just behind the top traded SNDL with over 326 million trading volume compared to the average volume of 6.1 million.

As we write this at 5:30 A.M. before hours, CRIS was continuing the bullish momentum trading at $7.06 up by 7.79%.

What’s Happening with the Biotech?

The Lexington-based biotech firm works on the development of innovative therapeutics that can help in treating cancer sufferers. Curis, Inc. is making progress with its CA-4948, a novel IRAK4 kinase inhibitor that can treat patientswith acute myeloid leukemia (AML).

The company in a press release reported that CA-4948 was successful in reducing marrow blast reductions in six patients. Among these six patients, two of them saw a marrow complete response. This reaction resulted in blast count dropping to 1% from 23% and 2% from 11% under the ongoing Phase 1 trial.

The positive aspect of the study is that all six participants are keeping up with the study. After obtaining Phase 1 study primary endpoints, Curis now focuses to attain proper dose levels of CA-4948 for a planned Phase 2 study.

Curis obtained highly encouraging results considering the fact that AML and MDS studies have proven underwhelming. The study in a relapsed setting is a difficult task to achieve but the company has recorded strong clinical activity with CA-4948 this early.

Moreover, the trial partners of the company have also done a great job in enrolling patients, keeping up with the pace of the study. Curis is looking forward to moving onto the next stage and report additional Phase 1 data in the second half of 2021.

In addition, Curis has also announced the plan to offer and sell its common stock shares in an underwritten public offering. The underwriters will have a 30-day option to buy additional common stock shares in an amount of 15% of the shares sold.

Curis, Inc. will use the net proceeds to advance CA-4948 development. Also, the biotech intends tocollaborate with Aurigene, and CI-8893, in partnership with ImmuNext. The rest of the net proceeds along with existing cash will be used for capital expenses and general working capital.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

8×8 Inc (EGHT) Joins hand with Verint Systems Inc. (VRNT)

8x8, Inc.(EGHT), a provider of communication solutions for the enterprise, and Verint Systems Inc. (NASDAQ: VRNT), a provider of security and optimization solutions for...

Don’t Ignore This Blaring Warning Signal from iRobot Corp (IRBT)

iRobot Corp. (NASDAQ: IRBT), a cleaning equipment manufacturer, experienced more than a 110% rise in its shares during the past 12 months. As a...

COVAX to receive up to 40 million doses of COVID-19 vaccine from Pfizer and BioNTech

The Coronavirus vaccine developed by Pfizer Inc. and BioNTech SE will provide 40 million doses to the COVAX vaccine distribution program, aiming to take...

PACCAR Inc (PCAR) Deal allows Aurora Autonomous Truck Validation

Aurora, a Silicon Valley-based autonomous driving startup with a $10 billion evaluation has entered a partnership with PACCAR Inc (PCAR),  to make light, medium...

Why Stratasys Ltd. (SSYS) Share Jumped over 12%?

The share price of Stratasys Ltd. (SSYS) jumped 12.53% to $35.84. A positive comment prompted the move, suggesting the company’s potential leadership in the...

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.